Three months' treatment with the α1-blocker alfuzosin does not affect total or transition zone volume of the prostate

Prostate Cancer and Prostatic Diseases

Volumn 9, Issue 2, 2006, Pages 121-125

  Roehrborn, Claus G ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

1 blocker; Alfuzosin; Apoptosis; Benign prostatic hyperplasia; Prostate volume

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; PLACEBO; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; QUINAZOLINE DERIVATIVE;

ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; STANDARDIZATION; STATISTICAL SIGNIFICANCE; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT DURATION; URINARY TRACT DISEASE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; MIDDLE AGED; NONPARAMETRIC TEST; PROBABILITY; TREATMENT FAILURE; URINE RETENTION;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; ORGAN SIZE; PROBABILITY; PROSTATIC HYPERPLASIA; QUINAZOLINES; STATISTICS, NONPARAMETRIC; TREATMENT FAILURE; URINARY RETENTION;

EID: 33745663261     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500849     Document Type: Article

References (13)

1. Algaba F. Pathophysiology of benign prostatic hyperplasia. Eur Urol 1994; 25 (suppl 1): 3-5.
2. Medina JJ, Parra RO, Moore RG. Benign prostatic hyperplasia (the aging prostate). Med Clin North Am 1999; 83: 1213-1229.
3. Akduman B, Crawford ED. Terazosin, doxazosin, and prazosin: Current clinical experience. Urology 2001; 58 (suppl 6A): 49-54.
4. 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol 1999; 161: 2002-2008.
5. 1-AR) antagonists on cell proliferation and apoptosis in the prostate: Therapeutic implications in prostatic disease. Prostate Suppl 2000; 9: 42-46.
6. Roehrborn CG, for the ALFUS Study Group. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A randomized, placebo-controlled trial. Urology 2001; 58: 953-959.
7. Terris MK, Stamey TA. Determination of prostate volume by transrectal ultrasound. J Urol 1991; 145: 984-987.
8. Kyprianou N, Litvak JP, Borkowski A, Alexander R, Jacobs SC. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol 1998; 159: 1810-1815.
9. McKeage K, Plosker GL. Alfuzosin: A review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs 2002; 62: 633-653.
10. 1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: Once daily versus 3 times daily dosing in healthy subjects. Int J Clin Pharmmacol Ther 2002; 40: 289-294.
11. Fulton B, Wagstaff AJ, Sorkin EM. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995; 49: 295-320.
12. Taguchi K, Schäfers RF, Michel MC. Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics. Br J Clin Pharmacol 1998; 45: 49-55.
13. Kyprianou N, Benning CM. Suppression of human prostate cancer cell growth by α1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res 2000; 60: 4550-4555.